	US 11,851,659 B2
	Compositions and methods for immunooncology
Jennifer Brogdon, Sudbury, MA (US); Ming-Wei Chen, Cambridge, MA (US); Hyungwook Lim, Newton, MA (US); Yi Yang, Belmont, MA (US); Morag Stewart, Boston, MA (US); and Sarah Hesse, Cambridge, MA (US)
Assigned to Novartis AG, Basel (CH); and Intellia Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 16/498,361
Filed by Novartis AG, Basel (CH); and Intellia Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Mar. 21, 2018, PCT No. PCT/US2018/023631 § 371(c)(1), (2) Date Sep. 26, 2019, PCT Pub. No. WO2018/175636, PCT Pub. Date Sep. 27, 2018.
Claims priority of provisional application 62/475,024, filed on Mar. 22, 2017.
Prior Publication US 2021/0071182 A1, Mar. 11, 2021
Int. Cl. C12N 9/22 (2006.01); C12N 15/86 (2006.01); C12N 15/113 (2010.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01)

CPC C12N 15/1138 (2013.01) [A61K 35/17 (2013.01); C07K 14/70503 (2013.01); C07K 14/70578 (2013.01); C12N 9/22 (2013.01); C12N 15/86 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2310/20 (2017.05); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01)]

44 Claims

1. A composition comprising:

a) a gRNA molecule or a nucleic acid sequence encoding the gRNA molecule, wherein the gRNA molecule comprises a tracr and crRNA, wherein the crRNA comprises a targeting domain that is complementary to a target sequence selected from a TET2 intron and a TET2 intron-exon junction, wherein the targeting domain is complementary to a sequence within a genomic region of chr4:105269748-105272563, wherein the location of the sequence within the genomic region is according to an alignment with the human reference genome hg38; and

b) a Cas9 molecule or a nucleic acid sequence encoding the Cas9 molecule, wherein the Cas9 molecule comprises an amino acid sequence of SEQ ID NO: 123.